Skip to main content

Table 1 NHERF1 in ependymal tumors and in other tumors considered in the differential diagnosis

From: NHERF1/EBP50 is an organizer of polarity structures and a diagnostic marker in ependymoma

Diagnosis Patients Site NHERF1 microlumen positivity
  No. cases gender Mean age (range)   Diffuse Focal Total/Site Total
Ependymoma 341 44.6 (121-74) ST: 51 5 (100%)   5 (100%) 34 (100%)
20M, 14F PF: 8 8 (100%)   8 (100%)
    SC:21 18 (85%) 32 (15%) 21 (100%)
Adult Anaplastic ependymoma 9 33 (23–49) ST: 7 2 (28%) 2 (28%) 4 (57%) 6 (67%)
5M, 4F PF: 1 1 (100%) 0 1 (100%)
    SC: 1 0 1 (100%) 1 (100%)
Pediatric Anaplastic ependymoma 5 4F, 1M 11.8 (6–17) ST: 3 2 (67%) 1 (33%) 3 (100%) 5 (100%)
PF: 2 2 (100%) 0 2 (100%)
Subependymoma 6 4M, 2F 60.5 (40–68) ST: 5 PF: 1 5 (100%) 1 (100%) 0 0 5 (100%) 1 (100%) 6 (100%)
Mixopapillary ependymoma 5 3F, 2M 45.6 (34–65) SC: 5 0 3 (60%) 3 (60%) 33 (60%)
Glioblastoma 151 7M, 8F 54.2 (121-76) ST: 13 PF: 21 0 0 3 (23%) 0 3 (23%) 0 3 (20%)
AT/RT 2 2F 0.75 (0.4-1.1) PF: 2 0 0 0 0%
Medulloblastoma 6 5M, 1F 24 (8–63) PF: 6 0 0 0 0%
Diffuse gliomas4 22 16M, 6F 46.5 (27–78) ST: 22 0 0 0 0%
Pilocytic astroc. 4 3M, 1F 31.5 (18,61) ST:1 PF: 2 SC: 1 0 0 0 0%
Schwannoma 5 3M, 2F 46 (29–56) PF: 4 SC: 1 0 0 0 0%
  1. M, male; F, female; ST, supratentorial; PF, posterior fossa; SC, spinal cord.
  2. 11pediatric case.
  3. 22 tanycytic and 1 giant cell ependymoma.
  4. 3All myxopapillary ependymomas had focal NHERF1 membranous staining and positive canals.
  5. 4Diffuse gliomas comprise oligodendroglioma WHO grade II (n = 5) and III (n = 1), oligoastrocytoma WHO grade II (n = 8) and III (n = 4), and astrocytoma WHO grade II (n = 1) and III (n = 3).